Sarepta Therapeutics Financial Statements (SRPT)

Sarepta Therapeuticssmart-lab.ru %   2019 2020 2021 2022 2023   LTM ?
Report date 26.02.2020 01.03.2021 01.03.2022 28.02.2023 28.02.2024   28.02.2024
Currency USD USD USD USD USD   USD
Financial report URL  
Revenue, bln rub ? 380.8 540.1 701.9 933.0 1 243   1 243
Operating Income, bln rub -522.3 -564.2 -449.7 -536.2 -267.8   -267.8
EBITDA, bln rub ? -469.4 -529.3 -412.1 -473.5 -267.8   -225.1
Net profit, bln rub ? -715.1 -554.1 -418.8 -703.5 -536.0   -536.0
OCF, bln rub ? -456.5 107.5 -443.2 -325.3 -501.0   -501.0
CAPEX, bln rub ? 62.7 82.2 38.5 30.8 87.3   87.3
FCF, bln rub ? -519.2 25.3 -481.7 -356.2 -588.3   -588.3
Dividend payout, bln rub 0.000 0.000 0.000 0.000 0.000   0.000
Ordinary share dividend yield, % 0.00% 0.00% 0.00% 0.00% 0.00%   0
Dividend payout ratio, % 0.00% 0.00% 0.00% 0.00% 0.00%   0
OPEX, bln rub 846.6 1 041 1 055 1 329 1 361   1 361
Cost of production, bln rub 56.6 63.4 97.0 140.0 150.3   150.3
R&D, bln rub 560.9 722.3 771.2 877.1 877.4   877.4
Interest expenses, bln rub 30.7 59.9 63.5 53.2 22.0   33.6
Assets, bln rub 1 823 2 985 3 148 3 128 3 265   3 265
Net Assets, bln rub ? 818.2 761.8 928.0 385.0 859.3   859.3
Debt, bln rub 729.6 1 073 1 138 1 617 1 397   1 397
Cash, bln rub 1 125 1 939 2 116 1 989 1 676   1 676
Net debt, bln rub -395.1 -865.7 -977.5 -372.0 -279.4   -279.4
Ordinary share price, rub 129.0 170.5 90.1 129.6 96.4   78.0
Number of ordinary shares, mln 73.6 78.0 81.3 87.6 92.4   93.6
Market cap, bln rub 9 499 13 291 7 318 11 346 8 910   7 302
EV, bln rub ? 9 104 12 425 6 340 10 974 8 630   7 023
Book value, bln rub 806 748 914 377 830   830
EPS, rub ? -9.71 -7.11 -5.15 -8.03 -5.80   -5.73
FCF/share, rub -7.05 0.32 -5.93 -4.07 -6.37   -6.28
BV/share, rub 10.9 9.60 11.2 4.31 8.98   8.86
EBITDA margin, % ? -123.3% -98.0% -58.7% -50.8% -21.5%   -18.1%
Net margin, % ? -187.8% -102.6% -59.7% -75.4% -43.1%   -43.1%
FCF yield, % ? -5.47% 0.19% -6.58% -3.14% -6.60%   -8.06%
ROE, % ? -87.4% -72.7% -45.1% -182.7% -62.4%   -62.4%
ROA, % ? -39.2% -18.6% -13.3% -22.5% -16.4%   -16.4%
P/E ? -13.3 -24.0 -17.5 -16.1 -16.6   -13.6
P/FCF -18.3 526.1 -15.2 -31.9 -15.1   -12.4
P/S ? 24.9 24.6 10.4 12.2 7.17   5.87
P/BV ? 11.8 17.8 8.01 30.1 10.7   8.80
EV/EBITDA ? -19.4 -23.5 -15.4 -23.2 -32.2   -31.2
Debt/EBITDA 0.84 1.64 2.37 0.79 1.04   1.24
R&D/CAPEX, % 894.4% 878.7% 2 004% 2 845% 1 005%   1 005%
CAPEX/Revenue, % 16.5% 15.2% 5.48% 3.30% 7.03%   7.03%
Sarepta Therapeutics shareholders